Ocular Therapeutix, Inc. News Releases http://investors.ocutx.com/ Ocular Therapeutix, Inc. News Releases en Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-present-three-upcoming-investor-1 BEDFORD, Mass. --(BUSINESS WIRE)--May 30, 2019-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor Thu, 30 May 2019 08:00:35 -0400 Ocular Therapeutix, Inc. News Releases 9471 Ocular Therapeutix™ Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA® http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-announces-receipt-c-code-and-pass-through BEDFORD, Mass. --(BUSINESS WIRE)--May 29, 2019-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Wed, 29 May 2019 08:00:03 -0400 Ocular Therapeutix, Inc. News Releases 9466 Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-announces-topline-results-phase-3-0 OTX-TP failed to meet primary endpoint but achieved statistically significant reduction of intraocular pressure versus placebo at eight of the nine pre-specified time points The Company plans to discuss the data from the clinical trial with the FDA and determine next steps BEDFORD, Mass. Mon, 20 May 2019 16:04:17 -0400 Ocular Therapeutix, Inc. News Releases 9461 Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-reports-first-quarter-2019-financial DEXTENZA ® Commercial Launch Scheduled for Mid-Year 2019 BEDFORD, Mass. --(BUSINESS WIRE)--May 10, 2019-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the Fri, 10 May 2019 07:29:16 -0400 Ocular Therapeutix, Inc. News Releases 9456 Ocular Therapeutix™ To Report First Quarter 2019 Financial Results http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-report-first-quarter-2019-financial-results BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter Thu, 02 May 2019 08:00:45 -0400 Ocular Therapeutix, Inc. News Releases 9451 Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutix-announces-dextenzar-dexamethasone-ophthalmic BEDFORD, Mass. --(BUSINESS WIRE)--May 1, 2019-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Wed, 01 May 2019 08:30:15 -0400 Ocular Therapeutix, Inc. News Releases 9446 Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc. http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutix-inc-settles-litigation-mati-therapeutics-inc BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has settled litigation with Tue, 30 Apr 2019 08:00:53 -0400 Ocular Therapeutix, Inc. News Releases 9336 Ocular Therapeutix™ to Present New Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-present-new-data-association-research Pooled safety and efficacy data for DEXENZA for the treatment of ocular pain and inflammation after ophthalmic surgery Safety and efficacy data for DEXTENZA for the treatment of allergic conjunctivitis Interim safety and efficacy data for OTX-TIC in subjects with glaucoma or ocular hypertension New Wed, 24 Apr 2019 08:00:59 -0400 Ocular Therapeutix, Inc. News Releases 9331 Ocular Therapeutix™ Reports Changes to Board of Directors http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-reports-changes-board-directors BEDFORD, Mass --(BUSINESS WIRE)--Apr. 23, 2019-- Ocular Therapeutix, Inc.  (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced the nomination of Seung Suh (Stanley) Hong , Tue, 23 Apr 2019 16:55:47 -0400 Ocular Therapeutix, Inc. News Releases 9326 Ocular Therapeutix™ to Present at the H.C. Wainwright Global Life Sciences Conference http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-present-hc-wainwright-global-life-sciences BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich , President and Wed, 03 Apr 2019 08:00:45 -0400 Ocular Therapeutix, Inc. News Releases 9076